- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Approves Biohaven’s Preventive Treatment for Episodic Migraine
Biohaven Pharmaceuticals has announced that FDA has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of adult patients with episodic migraine (e.g. those who experience less than 15 headache days per month.)
The new approval makes NURTEC ODT the first oral CGRP antagonist approved for the preventive treatment of migraine, and the only migraine medication approved as a dual therapy for both the acute and preventive treatment, the company reports.
NURTEC ODT is approved for acute treatment in all eligible adult patients with migraine, regardless of the number of monthly migraine days. Since approximately 95% of all US migraine patients experience less than 15 headache days per month, the new indication of preventive treatment ”significantly expands the market potential of NURTEC ODT and provides a new preventive treatment option for the vast majority of people living with migraine,” the company states.
William “BJ” Jones, Biohaven’s Chief Commercial Officer, Migraine & Common Disease, talks about the development of NURTEC ODT in his 2021 Emerging Pharma Leader profile.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
